Four Drugs Upfront Yield 'Unprecedented' Response in Myeloma

(MedPage Today) -- Adding the anti-CD38 drug daratumumab (Darzalex) to a weekly three-drug regimen for patients with newly diagnosed multiple myeloma led to extremely high rates of minimal residual disease (MRD) negativity in a single-arm study...